Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.
Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company focused on medicines for HIV, viral hepatitis, COVID‑19, cancer and inflammation. The GILD news feed highlights how the company’s research, collaborations and policy decisions translate into clinical programs, regulatory milestones and access initiatives across these therapeutic areas.
Investors and healthcare observers following GILD news will see regular updates on Gilead’s HIV portfolio, including clinical trial readouts such as the Phase 3 ARTISTRY‑1 and ARTISTRY‑2 studies of an investigational single‑tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. News also covers developments related to lenacapavir as a long‑acting option for HIV prevention and treatment, as well as agreements affecting key products like Biktarvy, including patent settlements disclosed by the company.
Oncology and cell therapy news is another major theme. Through Kite, a Gilead company, GILD‑related releases feature data on Yescarta for relapsed or refractory large B‑cell lymphoma, next‑generation bicistronic CAR T‑cell candidates KITE‑753 and KITE‑363 for B‑cell lymphomas, and anitocabtagene autoleucel (anito‑cel) for relapsed or refractory multiple myeloma. Updates often include efficacy and safety results from pivotal and early‑stage trials, as well as details on collaborations such as the partnership with Arcellx on anito‑cel and the research collaboration with OncoNano Medicine on ON‑BOARD encapsulation technology.
Gilead news also reflects broader corporate and policy activity, including agreements with the U.S. government related to drug pricing and access, philanthropic grants from the Gilead Foundation for metastatic breast cancer support, leadership appointments, investor conference presentations and quarterly financial announcements. Bookmark this page to monitor how these scientific, commercial, governance and access‑related developments shape the ongoing story of GILD.
Kite, a Gilead Company (GILD), announced promising results from the ZUMA-7 trial of Yescarta for treating large B-cell lymphoma (LBCL) in patients aged 65 and older. The trial showed Yescarta significantly outperformed standard of care (SOC) in two-year event-free survival (EFS) rates, achieving over three-fold higher in elderly patients. Median EFS was also markedly better at 21.5 months versus 2.5 months for SOC. Quality of life improvements were noted, alongside manageable safety profiles. The FDA recently expanded Yescarta's approval as an initial treatment for refractory LBCL.
Everest Medicines' licensing partner, Gilead Sciences (GILD), reported promising results from the Phase 3 TROPiCS-02 study of Trodelvy in HR+/HER2- metastatic breast cancer patients. The study achieved its primary endpoint of progression-free survival, showing a 34% reduction in the risk of disease progression or death (median PFS: 5.5 months vs. 4 months). Notably, 21% of patients treated with Trodelvy remained progression-free at the one-year mark, compared to 7% in the chemotherapy group. Trodelvy's safety profile was consistent with previous studies, indicating no new safety concerns.
Gilead Sciences announced positive results from the Phase 3 TROPiCS-02 study for Trodelvy in treating HR+/HER2- metastatic breast cancer. The study showed a 34% reduction in disease progression risk (median PFS: 5.5 vs. 4 months). At one year, 21% of Trodelvy patients were progression-free, compared to 7% for chemotherapy. A positive trend in overall survival was noted. The quality of life analysis indicated Trodelvy improved global health status and fatigue. No new safety issues emerged, although neutropenia and diarrhea were common. Trodelvy awaits regulatory approval for this indication.
Kite, a Gilead Company (GILD), announced findings from the largest real-world analysis of CAR T-cell therapy, Yescarta, focusing on racial and ethnic differences in outcomes for patients with relapsed or refractory large B-cell lymphoma (LBCL). The study revealed that Black or African American patients had longer times from diagnosis to treatment compared to White patients, potentially affecting response rates. Overall, Yescarta showed consistent efficacy across races. Findings were presented at the 2022 ASCO Annual Meeting, highlighting a need for further research on equity in CAR T-cell therapy access.
Gilead Sciences, Inc. has appointed Dr. Stacey Ma as the new Executive Vice President for Pharmaceutical Development and Manufacturing, effective July 18, 2022. She succeeds Dr. Taiyin Yang, who is retiring after 29 years with the company. Dr. Ma has over 25 years of experience in pharmaceutical development and manufacturing, previously serving as Executive Vice President at Sana Biotechnology. Gilead's CEO, Daniel O'Day, expressed confidence in Dr. Ma's leadership to maintain excellence in drug development and manufacturing during a time of portfolio diversification.
Summary not available.
Gilead Sciences (Nasdaq: GILD) and Kite will present over 20 abstracts at the 2022 ASCO Annual Meeting, including groundbreaking findings in breast and blood cancers. Notable studies include the TROPiCS-02 trial for HR+/HER2- breast cancer and analyses from the ZUMA-7 CAR T-cell therapy trial, highlighting treatment options for older patients. Additionally, data on MDS and AML treatment advancements will be showcased. These presentations underscore Gilead's commitment to addressing critical gaps in oncology care.
Gilead Sciences announced that the FDA has lifted the clinical hold on its Investigational New Drug Application for injectable lenacapavir, allowing all clinical studies to resume. This decision follows a review confirming the compatibility of lenacapavir with a new aluminosilicate glass vial. Previously, the hold was due to concerns over borosilicate vials. Lenacapavir is an investigational long-acting HIV treatment and prevention option. The company aims to progress this potential breakthrough, which would provide a biannual treatment option for patients.
Gilead Sciences has entered into a collaboration with Dragonfly Therapeutics to develop immunotherapies utilizing the novel NK cell engager technology. Gilead will receive exclusive worldwide rights to DF7001, a 5T4-targeting investigational candidate aimed at treating solid tumors. The deal includes a
Gilead Sciences reported first quarter 2022 revenue of $6.6 billion, a 3% increase year-over-year, aided by strong sales of Biktarvy ($2.2 billion, up 18%) and oncology products ($420 million, up 60%). However, diluted EPS fell to $0.02 due to a $2.7 billion impairment. Non-GAAP diluted EPS rose 4% to $2.12. The company updated its full-year EPS guidance to $3.00-$3.50, previously $4.70-$5.20. Gilead's cash and equivalents decreased to $6.8 billion. The ongoing expansion of its oncology portfolio and a strong pipeline are key growth drivers.